These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34002914)

  • 41. Association of Direct-Acting Antiviral Treatment With Mortality Among Medicare Beneficiaries With Hepatitis C.
    Kalidindi Y; Jung J; Feldman R; Riley T
    JAMA Netw Open; 2020 Jul; 3(7):e2011055. PubMed ID: 32692371
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis.
    Sanai FM; Altraif IH; Alswat K; AlZanbagi A; Babatin MA; AlMousa A; Almutairi NH; Aljawad MS; Alghamdi AS; Aljumah AA; Alalwan AM; Al-Hamoudi WK; Assiri AM; Dahlan Y; Alsahafi A; Alothmani HS; AlSaleemi MS; Mousa WA; Albenmousa A; Awny A; Albiladi H; Abdo AA; AlGhamdi H
    J Infect; 2018 Jun; 76(6):536-542. PubMed ID: 29742470
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of the Hepatitis C Continua of Care Between Hepatitis C Virus/HIV Coinfected and Hepatitis C Virus Mono-Infected Patients in Two Treatment Eras During 2008-2015.
    Roberson JL; Lagasca AM; Kan VL
    AIDS Res Hum Retroviruses; 2018 Feb; 34(2):148-155. PubMed ID: 28974107
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Change in hepatitis C virus positivity among needle-stick injury source patients: a 10-year experience in a Japanese tertiary hospital.
    Okushin K; Suzuki R; Tsutsumi T; Okamoto K; Ikeuchi K; Kado A; Minatsuki C; Minami-Kobayashi Y; Satoh N; Ikeda M; Harada S; Enooku K; Fujinaga H; Yotsuyanagi H; Koike K; Moriya K
    BMC Infect Dis; 2021 Apr; 21(1):399. PubMed ID: 33931015
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatitis C care cascade before and during the direct-acting antiviral eras in New South Wales, Australia: A population-based linkage study.
    Yousafzai MT; Alavi M; Valerio H; Hajarizadeh B; Grebely J; Dore GJ
    J Viral Hepat; 2023 Mar; 30(3):250-261. PubMed ID: 36537024
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
    Goel A; Bhargava R; Rai P; Aggarwal R
    Indian J Gastroenterol; 2017 May; 36(3):227-234. PubMed ID: 28656492
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.
    Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Coppola C; Ciancio A; Bruno SR; Loi M; Giorgini A; Margotti M; Cossiga V; Brancaccio G; Dallio M; De Siena M; Cannizzaro M; Cavalletto L; Massari M; Mazzitelli M; De Leo P; Laccabue D; Baiocchi L; Kondili LA
    BMC Infect Dis; 2021 May; 21(1):413. PubMed ID: 33947337
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
    Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
    Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure.
    Lu M; Wu KH; Li J; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Daida YG; Schmidt MA; Rupp LB; Zhang T; Trudeau S; Gordon SC
    J Viral Hepat; 2019 Oct; 26(10):1210-1217. PubMed ID: 31197910
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis.
    Merchante N; Rivero-Juárez A; Téllez F; Merino D; Ríos-Villegas MJ; Villalobos M; Omar M; Rincón P; Rivero A; Pérez-Pérez M; Raffo M; López-Montesinos I; Palacios R; Gómez-Vidal MA; Macías J; Pineda JA;
    J Antimicrob Chemother; 2018 Sep; 73(9):2435-2443. PubMed ID: 29982683
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.
    Janjua NZ; Islam N; Wong J; Yoshida EM; Ramji A; Samji H; Butt ZA; Chong M; Cook D; Alvarez M; Darvishian M; Tyndall M; Krajden M
    J Viral Hepat; 2017 Aug; 24(8):624-630. PubMed ID: 28130810
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
    Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
    Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleeding.
    Moon AM; Green PK; Rockey DC; Berry K; Ioannou GN
    Aliment Pharmacol Ther; 2020 Feb; 51(3):364-373. PubMed ID: 31773763
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Retransplantation outcomes for hepatitis C in the United States before and after direct-acting antiviral introduction.
    Ivanics T; Rizzari M; Moonka D; Al-Kurd A; Delvecchio K; Kitajima T; Elsabbagh AM; Collins K; Yoshida A; Abouljoud M; Nagai S
    Am J Transplant; 2021 Mar; 21(3):1100-1112. PubMed ID: 32794649
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical outcomes in HIV+/HCV+ coinfected kidney transplant recipients in the pre- and post-direct-acting antiviral therapy eras: 10-Year single center experience.
    Camargo JF; Anjan S; Chin-Beckford N; Morris MI; Abbo LM; Simkins J; Ciancio G; Chen LJ; Burke GW; Figueiro J; Guerra G; Kupin WL; Mattiazzi A; Ortigosa-Goggins M; Ram Bhamidimarri K; Roth D
    Clin Transplant; 2019 May; 33(5):e13532. PubMed ID: 30866102
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reversion of disease manifestations after HCV eradication.
    van der Meer AJ; Berenguer M
    J Hepatol; 2016 Oct; 65(1 Suppl):S95-S108. PubMed ID: 27641991
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nonalcoholic Fatty Liver Disease Risk Factors Affect Liver-Related Outcomes After Direct-Acting Antiviral Treatment for Hepatitis C.
    Benhammou JN; Moon AM; Pisegna JR; Su F; Vutien P; Moylan CA; Ioannou GN
    Dig Dis Sci; 2021 Jul; 66(7):2394-2406. PubMed ID: 32654086
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care.
    Cachay ER; Wyles D; Hill L; Ballard C; Torriani F; Colwell B; Kuo A; Schooley R; Mathews CW
    Open Forum Infect Dis; 2015 Dec; 2(4):ofv168. PubMed ID: 26697509
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
    Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW
    S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.